Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Treatment options for metastatic prostate cancer (mPC) are limited following docetaxel (Taxotere) failure.
• Current FDA-approved therapies (cabazitaxel, sipuleucel-T, abiraterone) offer limited survival benefits due to low response rates and inherent drug resistance.
• There is a critical need for novel therapeutic strategies in advanced prostate cancer.

Observation:

• A patient with metastatic prostate cancer progressed despite multiple lines of therapy, including LHRH agonist, bicalutamide, docetaxel, and doxorubicin.
• Molecular profiling revealed androgen receptor (AR) overexpression.
• The patient received second-line hormonal therapy guided by molecular profiling.

Findings:

• The patient exhibited a dramatic and measurable response to a combination therapy including ketoconazole, estrogen, and Leukine, selected based on AR overexpression.
• This case demonstrates the potential of molecular profiling to guide treatment selection in refractory metastatic prostate cancer.
• Hormonal therapy, when tailored to molecular characteristics, can be effective even after extensive prior treatments.

Implications:

• Gene expression profiling can identify patients likely to respond to specific therapies, improving treatment efficacy in metastatic prostate cancer.
• Personalized medicine approaches, guided by molecular diagnostics, offer a promising alternative to standard treatment algorithms.
• This case highlights the potential of targeting AR signaling with novel hormonal agents in resistant prostate cancer settings.